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on the Efﬁcacy and Safety of the Selective
A2A Agonist Regadenoson Versus Adenosine
in Myocardial Perfusion Imaging
Integrated ADVANCE-MPI Trial Results
Manuel D. Cerqueira, MD, FACC,* Patricia Nguyen, MD,† Peter Staehr, MD,†
S. Richard Underwood, MD, FACC,‡ Ami E. Iskandrian MD, MACC,§ on behalf of
the ADVANCE-MPI Trial Investigators
Cleveland, Ohio; Palo Alto, California; London, England; and Birmingham, Alabama
O B J E C T I V E S To compare the effects of age, gender, body mass index, and diabetes on the safety
and efﬁcacy of regadenoson stress myocardial perfusion imaging, and to assess the noninferiority of
regadenoson to adenosine for the detection of reversible myocardial perfusion defects.
B A C KG ROUND Previous reports have shown that a ﬁxed unit bolus of regadenoson is safe and
noninferior to adenosine for the detection of reversible perfusion defects by radionuclide imaging.
METHOD S Using a database of 2,015 patients, we evaluated the effects of age, gender, body mass
index, and diabetes on the safety and efﬁcacy of regadenoson compared to adenosine.
R E S U L T S For detection of ischemia relative to adenosine, noninferiority was demonstrated for all
patients (agreement rate difference 0%, 95% CI6.2% to 6.8%). The average agreement rate between
adenosine-adenosine and adenosine-regadenoson were 0.62  0.03 and 0.63  0.02. Detection of
ischemia was also comparable in speciﬁc subgroups. Agreement was less for both agents in women
versus men with moderate and large areas of ischemia. Compared to adenosine, regadenoson had a
lower combined symptom score and less chest pain, ﬂushing, and throat, neck, or jaw pain, but more
headache and gastrointestinal discomfort. This was true in nearly all subgroups. Regadenoson patients
reported feeling more comfortable (1.7  .02 vs. 1.9  0.03, p  0.001). Based on the overall tolerability
score, women felt less comfortable than men with both stress agents. Image quality was rated good or
excellent in 92% for both agents.
CONC L U S I O N S Regadenoson can be safely administered as a ﬁxed unit bolus and is as efﬁcacious
as adenosine in detecting ischemia regardless of age, gender, body mass index, and diabetes.
Regadenoson is better tolerated overall and across various subgroups. (J Am Coll Cardiol Img 2008;1:
307–16) © 2008 by the American College of Cardiology Foundation
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308denosine and dipyridamole are the most com-
monly used pharmacologic stress agents with
single photon emission computed tomog-
raphy (SPECT) for myocardial perfusion
maging (MPI) (1). These agents stimulate all 4
denosine receptor subtypes, each with unique
harmacologic properties (2,3). The A2A receptor
timulation causes the differential coronary arterial
ilation required for SPECT MPI. Activation of
he other receptors causes undesired symptoms and
afety concerns that mandate rigorous pre-screening
nd monitoring (4,5). Furthermore, these agents
equire weight-adjusted dosing and a continuous
nfusion pump, adding additional steps and increas-
ng the potential for dosing errors (6).
See page 317
Regadenoson, a selective A2A adenosine receptor
gonist, is administered as a fixed unit bolus that
induces a 2- to 3-fold increase in myocar-
dial blood flow for 3 to 4 min (7,8). The
ADVANCE MPI 1 and 2 (ADenoscan
Versus regAdenosoN Comparative Evalu-
ation for Myocardial Perfusion Imaging)
trials are multicenter phase 3 trials de-
signed to demonstrate noninferiority of
regadenoson compared to adenosine (9–
11). The results of ADVANCE MPI 2
(12) have shown that regadenoson is non-
inferior to adenosine for the detection of
reversible defects and is safe and better
tolerated. The results of the second trial
are presented with the combined dataset
ncluding specific subgroup analyses (1,5,13).
The goals of this investigation were: 1) to com-
are the efficacy, safety, and tolerability of adeno-
ine and regadenoson stress MPI in the subgroups
f age, gender, body mass index (BMI), and diabe-
es (DM); and 2) to further assess the noninferiority
f regadenoson to adenosine for the detection of
eversible myocardial perfusion defects.
E T H O D S
tudy design and stress protocol. We combined data
rom 2 identical double-blind, randomized, active-
omparator, double dummy, multicenter phase 3
rials designed to show that the strength of agree-
ent between sequential adenosine-regadenoson
mages is noninferior to the strength of agreement
etween sequential adenosine images. Informed
core
ssiononsent was obtained in all patients. All patients aad an adenosine study and were randomized to
ither regadenoson or adenosine in a 2 to 1 ratio.
he trial protocols limited the number of patients
ith “no to minimal” reversible defects based on the
ite investigator’s interpretation of the initial aden-
sine study to 50% of the total number random-
zed to guarantee assessment across the full range of
isease severity (14).
atient population, imaging protocols, and SPECT
nalysis. The criteria for patient enrollment were
dentical in the 2 trials (12). All images were
cquired according to guidelines (12,15). Separately
or each trial, 3 expert readers independently scored
he blinded images using a 17-segment model on a
-point scale from 0  normal to 4  no activity
4). Segments were reversible if the stress score was
reater than the rest score and the stress score was
2. Reversible defects were categorized as 0 to 1
no to minimal), 2 to 4 (small to moderate), or 5
large). Readers also assessed the overall diagnosis
normal, ischemia, ischemia  scar, scar) and over-
ll image quality. When evaluating image quality,
eaders assessed lung uptake and subdiaphragmatic
nterference and recorded any evidence of excessive
ardiac motion or breast shadow.
eported symptom evaluation and hemodynamic.
eported symptoms following the randomized in-
usion were collected and rated as mild, moderate,
r severe. In a pre-defined analysis, symptoms were
ombined into 7 groups corresponding to adverse
eactions occurring with frequency greater than
0% according to the Adenoscan label. Summed
cores on a scale of 0  not reported to 3  severe
ere calculated for the 3 most frequent groups,
flushing,” “chest pain,” and “dyspnea,” and for all 7
ymptom groups. Hemodynamic measurements
ere performed at baseline and frequently over 45
in after dosing.
olerability questionnaire. At completion of the ran-
omized study, patients were asked to rate how they
elt using a 4-point scale of 1  comfortable, 2  a
ittle uncomfortable, 3  very uncomfortable, 4 
xtremely uncomfortable. Patients were also asked
ow the second randomized procedure compared to
he initial adenosine study using a 5-point scale
1  much better, 2  somewhat better, 3  about
he same, 4  somewhat worse, 5  much worse).
T A T I S T I C A L A N A L Y S I S
emographic and baseline characteristics are sum-
arized by median and range or count and percent-B B R E V I A T I O N S
N D A C R O N YM S
V atrioventricular
MI bodymass index
M diabetes mellitus
PImyocardial perfusion
maging
DS summed difference s
PECT Single photon emi
omputed tomographyge. Coronary artery disease risk was categorized
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309ased on the estimated pre-test probability of cor-
nary artery disease (16).
The primary agreement measure was an average
ate of agreement of the randomized study with the
nitial adenosine study on ischemia size category (0
o 1, 2 to 4, or 5 reversible defects using the
edian count across the 3 blinded readers). The
verage agreement rate was calculated as the equally
eighted average across the 3 initial study catego-
ies: (1/3) (agreement rate for initial category 0 to 1
eversible segments)  (1/3) (agreement rate for
nitial category 2 to 4 reversible segments)  (1/3)
agreement rate for initial category 5 reversible
egments). If the randomized study assessment is
tatistically independent of the initial assessment,
he chance agreement rate is one-third when the
nitial study categories are weighted equally. The
ange from chance to perfect agreement on the
verage agreement scale is, therefore, 33.3% to
00%. Based on previous work (17), a 20% differ-
nce on a kappa scale of 0% (chance agreement) to
00% (perfect agreement) is considered substantial.
ence, a 20% difference on the average agreement
cale ranging from chance agreement (33.3%) to
erfect agreement (100%) is 13 1/3%, and therefore
noninferiority margin of 13 1/3% was selected.
The primary analysis tested the null hypothesis of
nferiority of adenosine-regadenoson agreement to
denosine-adenosine agreement versus noninferior-
ty. A 95% confidence interval for the difference
etween adenosine-regadenoson average agreement
ate and repeat adenosine average agreement rate is
alculated and the null hypothesis rejected when the
ower limit is above 13 1/3%. Because the lower
imit has a confidence coefficient of 97.5%, this
orresponds to a 1-sided test at the 2.5% signifi-
ance level (9–11).
For the secondary efficacy analysis, summed
tress score (SSS) was calculated as the rounded
verage of the 3 reader SSS values. Summed differ-
nce score (SDS) was calculated as the rounded
verage of the 3 reader SDS values, which were
alculated as the sum of the positive stress–rest
core differences. Mean and standard deviation of
he difference between SDS and SSS scores from
he initial and randomized scan are calculated.
The overall diagnostic categories of (normal,
schemia, ischemia  scar, scar) were collapsed into
he presence (ischemia, ischemia  scar) and ab-
ence (normal, scar) of ischemia. Scores from the
olerability questionnaires 1 and 2 were collapsed
nto “comfortable” (1 and 2) and “uncomfortable” (3 mnd 4) and into “better” (1 and 2), “the same” (3),
nd “worse” (4 and 5), respectively.
Exploratory analyses were performed on the fol-
owing subgroups: age (65 or 65 years), male or
emale gender, BMI (30 kg/m2 or 30 kg/m2),
nd history or no history of DM.
All tests were performed at the 5% significance
evel, without adjusting for multiple comparisons.
ilcoxon’s rank sum tests were used to compare
eans of continuous variables and chi-square and
ochran-Mantel-Haenszel tests were used to com-
are categorical variables.
E S U L T S
andomization. Of the 3,469 patients with an initial
denosine study, 1,135 patients with normal images
ere not randomized to meet the pre-defined limit
50% in the 0 to 1 category). Forty-nine patients
ere not randomized due to major symptoms with
he initial adenosine infusion. The efficacy analysis
et included 1,871 patients (regadenoson 1,240,
denosine 631); 115 were withdrawn due to lack of
efects assessed by the central lab after closure to
he 0 to 1 category and 32 were withdrawn because
f incomplete imaging data. Three patients were
xcluded because of nonevaluable safety data, leav-
ng 2,015 patients (regadenoson 1,337, adenosine
78) in the safety analysis set. Efficacy analysis
ncluded 31% females, 55% 65 years, 38% BMI
30 kg/m2, and 32% DM. The safety analysis
ncluded 30% female, 56% 65 years, 38% BMI
30 kg/m2, and 33% DM. Subgroup proportions
ere similar for regadenoson and adenosine.
Baseline and demographic characteristics were
omparable for both groups, including type of
maging protocol used and extent of ischemia on
nitial adenosine scan (Table 1, p is not significant
or all comparisons) based upon the overall diagno-
is determined by the central readers. Analysis by
ubgroups shows that patients 65 years old were
ore likely to be female, much less likely to be
bese, and slightly less likely to have a reported
istory of DM; male patients were less likely to be
bese and slightly less likely to have a reported
istory of DM; and obese patients were very much
ore likely to have a reported history of DM.
ence, as might be expected, age, gender, obesity,
nd DM are all confounded, and the association
etween DM and obesity is particularly strong.
fﬁcacy primary end point. In the 1,871 patients
ncluded in combined analysis (Fig. 1), the agree-ent rates between the initial adenosine and ran-
percutaneous coronary intervention; PTCA  percutaneous transluminal coronary angioplasty.
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310Agreement Rate Difference and 95% CI:  0% (-6.2%, 6.8%)
Ischemia Extent No to Small to
  Minimal Moderate Large Rate±SE
 
 No to Minimal 362 54 14 .84±.02
 
 Small to 46 78 23 .53±.04
 Moderate
 
 Large 11 16 27 .50±.07
Average            Adenosine .62±.03Agreement
Adenosine Regadenoson
In
iti
al
 A
de
no
si
ne
 No to Small to
 Minimal Moderate Large Rate±SE
 
 706 109 19 .85±.01
 
 101 144 49 .49±.03
 
 
 13 38 61 .54±.05
                 
Regadenoson .63±.02
Figure 1. Agreement Rates for Ischemia in Combined ADVANCE MPI 1 and 2
In 1,871 subjects, 3 blinded experts independently scored images on a 5-point scale using 17-segments and ischemia was categorized
as 0 to 1 (no to minimal), 2 to 4 (small to moderate), or 5 (large). The overall average ischemia agreement rates between adenosine–
adenosine and adenosine–regadenoson was 0.62  0.03 and 0.63  0.02 with an agreement difference of 0% (95% CI 6.2% to 6.8%),
respectively. Regadenoson was noninferior to adenosine for detection of ischemia. ADVANCE MPI ADenoscan Versus regAdenosoNTable 1. Demographic and Baseline Characteristics and Medical History of Patients Included in ADVANCE MPI 1 and 2 Efﬁcacy
Analyses (n  1,871)
Characteristic
Adenosine
n  631
Regadenoson
n  1,240
p
Value*
Age, yrs, median (range) 65 (26–91) 66 (27–93) 0.45
Male, n (%) 430 (68) 864 (70) 0.50
Caucasian, n (%) 472 (75) 935 (75) 0.78
BMI, kg/m2, median (range) 28 (18–59) 29 (16–57) 0.47
Left ventricular ejection fraction 35%, n (%)† 553 (91) 1,084 (91) 0.63
Medical history, n (%)
CAD 475 (75) 966 (78) 0.20
Hypertension 502 (80) 1012 (82) 0.28
Angina 387 (61) 789 (64) 0.33
CABG, PTCA, or PCI 323 (51) 627 (51) 0.80
MI 270 (43) 494 (40) 0.22
Arrhythmia 204 (32) 418 (34) 0.55
Diabetes 213 (34) 394 (32) 0.39
CHF 109 (17) 226 (18) 0.61
COPD 34 (5) 66 (5) 0.95
Estimated pretest probability of CAD 90%, n (%)‡ 436 (69) 851 (69) 0.84
Imaging protocol 0.45
1-day 99mTc 193 (31) 415 (33)
2-day 99mTc 288 (46) 541 (44)
Dual isotope (201Tl rest, 99Tc stress) 150 (24) 284 (23)
Days between initial adenosine and randomized scans (median) 7 7 0.71
Initial adenosine study results§ 0.48
Normal 37% 35%
Scar 15% 15%
Ischemia 25% 25%
Ischemia and scar 23% 25%
*For continuous variables (i.e., age, BMI, days between scans), approximate Wilcoxon’s rank sum test p was used for comparing means. For categorical variables,
chi-square test p was used for comparing proportions. †Data were not available in all patients: missing data in adenosine  22 (3%), regadenoson  55 (4%). ‡Note:
Patients with a history of MI or revascularization were reassigned to the “ 90%” category. §Approximate p was used for comparing proportions with “reversible
defects” or “ﬁxed and reversible defects.”
ADVANCE MPI  ADenoscan Versus regAdenosoN Comparative Evaluation for Myocardial Perfusion Imaging; BMI  body mass index; CABG  coronary artery
bypass graft; CAD  coronary artery disease; CHF  congestive heart failure; COPD  chronic obstructive pulmonary disease; MI  myocardial infarction; PCI Comparative Evaluation for Myocardial Perfusion Imaging; CI  conﬁdence interval; SE  standard error.
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311omized adenosine or regadenoson imaging were
lmost identical (rate difference 0%, 95% CI6.2%
o 6.8%) and a lower limit of 6.2%, thereby
eeting the noninferiority requirement (9,17,18).
he average agreement rate between adenosine-
denosine and adenosine-regadenoson were 0.62 
.03 and 0.63 0.02, respectively. For both agents,
he interpretation agreement rate was best for the
roup with no or minimal ischemia.
Within age, gender, BMI, and DM subgroups,
denosine and regadenoson average agreement rates
ere similar, and adenosine and regadenoson agree-
ent rates were also similar for each initial study
schemia size category. For both adenosine and
egadenoson, average agreement rates ranged from
50% to 60% across all subgroups. In general,
greement rates were highest in the no ischemic
ategory (80%) and lowest in the moderate to
arge ischemia extent categories (50%). For
oth adenosine and regadenoson, agreement rates
ere lower in females than in males for the initial
tudy categories 2 to 4 and 5 reversible segments
Table 2).
fﬁcacy secondary end points. For both adenosine-
denosine and adenosine-regadenoson, mean SSS
ifferences were close to 0 and standard deviations
ere similar for the 2 arms for ADVANCE MPI 1
nd 2, respectively: adenosine-adenosine mean 
D  0.1  3.5 and 0.4  4.6; adenosine-
egadenoson mean  SD  0.0  3.5 and 0.3 
.2. The same was true of SDS: adenosine-
denosine mean  SD  0.1  3.2 and 0.6  3.9;
denosine-regadenoson mean  SD  0.0  3.1
nd 0.1  3.8 (Fig. 2).
Table 2. Ischemia Size Category Agreement Rates Between Initi
Subgroup
Adenosine–Adenosine
Average 0 to 1 2 to 4
Age, yrs
65 56% (298) 81% 52%
65 68% (333) 87% 54%
Gender
Female 57% (201) 88% 41%
Male 64% (430) 82% 57%
BMI, kg/m2
30 64% (389) 86% 59%
30 60% (242) 82% 44%
History of diabetes
Yes 59% (213) 84% 54%
No 63% (418) 84% 52%
*The 95% conﬁdence interval for adenosine-regadenoson average agreement r
CI  conﬁdence interval; DM  diabetes mellitus; other abbreviations as in TableOverall and for each subgroup, agreement rates
ere comparable for the presence and absence of
schemia. The average agreement rates between
denosine-adenosine and adenosine-regadenoson
ere 0.76  0.03 and 0.77  0.02 for the presence
nd 0.77 0.02 and 0.78 0.02 for the absence of
schemia, respectively.
For each stress agent, secondary end point simple
greement rates were also similar across age, sex,
MI, and DM subgroups.
mage quality. The majority of images were rated
ood or excellent (92%). Image quality was better in
en compared with women for both stress agents
p  0.001). For both stress agents, image quality
as similar for nonobese and obese patients, for
atients with and without a history of DM, and for
atients 65 and 65 years of age.
afety and tolerability. Comparing the incidences of
re-defined symptom groups (Table 3), regadeno-
on patients had a significantly reduced incidence of
hest pain, flushing, and throat, neck, or jaw pain
ut significantly more headache and gastrointestinal
iscomfort (p  0.05). These differences were
imilar across all subgroups.
Patients receiving regadenoson had a signifi-
antly lower mean summed score for the combina-
ion of chest pain, dyspnea, and flushing (0.9 
.03 vs. 1.3  0.05, p  0.05) and the mean
emained significantly lower when all symptoms
ere included (1.75  0.05 vs. 1.94  0.07, p 
.05). For patients receiving both regadenoson and
denosine, females reported a higher summed
ymptom score than males. For regadenoson alone,
denosine and Repeat Adenosine or Regadenoson by Age, Gende
Agreement Rate for Reversible Ischemia (n)
Adenosine–Regadenoson
>5 Average 0 to 1 2 to 4 >5
35% 63% (544) 86% 50% 52%
64% 63% (696) 84% 48% 58%
42% 54% (376) 87% 35% 40%
52% 65% (864) 83% 52% 59%
47% 62% (770) 83% 47% 56%
55% 64% (470) 87% 52% 53%
38% 62% (394) 81% 48% 56%
54% 63% (846) 86% 50% 53%
inus repeat adenosine average agreement rate.al A r, BMI, and DM
95% CI for
Difference*
3%, 16%
14%, 4%
16%, 11%
6%, 8%
10%, 7%
7%, 14%
9%, 15%
8%, 8%
ate m
1.
Ado  adenosine; GI  g
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Figure 2. Comparison of SSS and SDS for Initial Adenosine and Randomized Scan
Using the rounded average of 3 readers for adenosine-adenosine and adenosine-regadenoson scoring, mean summed stress score (SSS)
(A) and summed difference score (SDS) (B) differences were close to 0 and standard deviations (SDs) were similar for the 2 arms for the
ADVANCE MPI 1 and 2 trials. The differences between the initial adenosine and randomization to regadenoson were no different than
randomization to repeat adenosine. Results of ADVANCE MPI 1 are shown.Table 3. Symptom Group Incidence by Stress Agent, Age, Gender, BMI, and DM
Any Symptom
Group Chest Pain Dyspnea Flushing GI Discomfort Headache
Lightheadedness/
Dizziness
Throat, Neck,
or Jaw Pain
Ado Reg Ado Reg Ado Reg Ado Reg Ado Reg Ado Reg Ado Reg Ado Reg
All patients 79%* 73%* 41%* 29%* 26% 28% 34%* 22%* 17%* 23%* 17%* 26%* 7% 8% 14%* 7%*
Age, yrs
65 80% 75% 43%* 32%*† 27% 30% 32%* 22%* 20% 23% 17%* 29%* 7% 9% 16%* 7%*
65 77%* 72%* 40%* 26%*† 25% 27% 35%* 21%* 14%* 24%* 17%* 24%* 6% 7% 11%* 7%*
Gender
Female 87%* 80%*† 48%* 36%*† 28% 31% 34%* 17%*† 22%* 32%*† 23%* 37%*† 8% 7% 17%* 9%*
Male 75% 70%† 38%* 25%*† 25% 27% 34%* 23%*† 14%* 20%*† 14%* 22%*† 6% 9% 12%* 6%*
BMI, kg/m2
30 76% 73% 39%* 29%* 23% 27% 30%* 21%* 16%* 24%* 16%* 25%* 6% 9% 12%* 8%*
30 83%* 73%* 46%* 28%* 29% 29% 39%* 23%* 18% 22% 19%* 27%* 8% 7% 17%* 6%*
History of DM
Yes 79% 73% 40%* 29%* 27% 24%† 33%* 22%* 21% 25% 14%* 25%* 7% 6%† 17%* 5%*
No 78%* 73%* 42%* 28%* 25% 30%† 34%* 21%* 14%* 23%* 19%* 27%* 7% 9%† 12%* 8%*
Predeﬁned symptom groups occurring with adenosine: chest pain (angina, chest discomfort, chest pain, noncardiac chest pain), dyspnea (bronchospasm, dyspnea, wheezing, tachypnea), ﬂushing
(erythema, feeling hot, ﬂushing), GI discomfort (abdominal discomfort, distension, pain, diarrhea, nausea, vomiting), headache (tension headache, headache), lightheadedness/dizziness
(dizziness), throat, neck, jaw pain (muscle tightness, nasopharyngeal disorder, or neck, jaw, pharyngeal pain or discomfort). *Approximate chi-square test of equality of regadenoson and
adenosine rates, p  0.05. †Approximate chi-square test of equality of regadenoson rates across subgroups, p  0.05.astrointestinal; Reg  regadenoson; other abbreviations as in Tables 1 and 2.
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313atients 65 years reported a higher summed
ymptom score than patients 65.
olerability questionnaire—level of comfort with the
andomized test. Patients randomized to regadeno-
on felt more comfortable compared to patients
andomized to adenosine (92% vs. 81%) as demon-
trated by a significantly lower tolerability score for
egadenoson compared to adenosine (1.7 0.02 vs.
.9  0.03, p  0.001). Patients within each
ubgroup also reported feeling more comfortable
ith regadenoson. Based on the tolerability score,
omen reported feeling more uncomfortable than
en did after receiving both regadenoson and
denosine.
olerability questionnaire—comparing the random-
zed test to initial adenosine. When patients were
sked how the second test compared to the first
Table 4), 62% of those receiving regadenoson said
t felt better versus 43% of those receiving adeno-
ine. The average tolerability score for regadenoson
as much lower than adenosine (2.2  0.03 vs. 2.6
0.04, p  0.001), indicating a preference for
egadenoson. Patients across all subgroups also
avored regadenoson over adenosine (Table 4).
emodynamics. Hemodynamics were similar to
hose previously reported in ADVANCE MPI 2
12) with no significant differences between
ubgroups.
CG analysis. First-degree atrioventricular (AV)
lock (PR prolongation 220 ms) was noted in 34
2.8%) regadenoson patients and 43 (7.0%) adeno-
ine patients and second-degree AV block in 1
0.1%) regadenoson patient and 9 (1.5%) adenosine
Table 4. Tolerability Question 2: Responses and Overall Tolerab
Better
(Score 1 to 2)
Same
(Score 3)
Ado Reg Ado Reg
All patients 43% 62% 41% 24%
Age, yrs
65 46% 67% 38% 19%
65 40% 58% 43% 29%
Gender
Female 45% 64% 32% 20%
Male 42% 61% 45% 27%
BMI, kg/m2
30 43% 57% 42% 27%
30 42% 69% 38% 21%
History of diabetes
Yes 45% 63% 39% 25%
No 42% 61% 42% 24%
Question 2: How does this test compare to the ﬁrst (initial open label adenosine
adenosine means, p  0.05. †Approximate Cochran-Mantel-Haenszel test of eq
SE  standard error; other abbreviations as in Tables 1 and 3.atients (p  0.001). The second-degree AV block
f 1 beat at 3.5 min following regadenoson bolus
as in a patient with baseline first-degree AV block
nd PR-related changes most consistent with atyp-
cal Wenckebach. Third-degree block did not oc-
ur. None of the episodes required intervention.
I S C U S S I O N
n a large diverse high risk patient population using
arious imaging protocols and nuclear tracers, rega-
enoson is noninferior to adenosine for the detec-
ion of reversible myocardial perfusion defects (9–
1,17,18). Regadenoson can be safely administered
s a unit bolus with good to excellent image quality.
here were no clinical differences in efficacy or safety
etween the 2 agents overall and by age, gender, BMI,
r DM. Regadenoson was better tolerated than aden-
sine based on patient questionnaires.
2A selectivity. ADVANTAGE OF REGADENOSON.
ecause of its high A2A adenosine receptor selec-
ivity, regadenoson offers advantages over adenosine
7,8,12). The safety profile of regadenoson may
eflect its improved selectivity for the A2A receptor.
atients receiving regadenoson reported less flush-
ng, chest pain, and throat, neck, or jaw pain,
ossibly reflecting less stimulation of peripheral
denosine receptors by regadenoson. Moreover,
ewer cases of AV nodal block were seen, which is
onsistent with the weak activity on the A1 aden-
sine receptor. Patients receiving regadenoson,
owever, reported headache more frequently, which
ay result from differences in the degree of vaso-
Score for Patients Receiving Adenosine and Regadenoson
Worse
(Score 4 to 5) Mean Score  SE
Ado Reg Ado Reg
17% 14% 2.62 0.038* 2.17 0.031*
15% 14% 2.56 0.056* 2.080.046*†
17% 14% 2.67 0.053* 2.23 0.041*†
23% 17% 2.68 0.078* 2.20 0.059*
13% 13% 2.59 0.043* 2.15 0.036*
14% 16% 2.58 0.048* 2.30 0.040*†
19% 10% 2.680.065* 1.950.046*†
17% 12% 2.53 0.070* 2.14 0.052*
16% 15% 2.660.046* 2.180.038*
t? *Approximate Cochran-Mantel-Haenszel test of equality of regadenoson and
y of regadenoson means across subgroups, p  0.05.ility
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314ilation and sympathetic stimulation produced by
he 2 stress agents, which has been noted in animal
odels (19).
ixed unit bolus. Unlike other agents, regadenoson
an be safely administered as a fixed unit bolus
ecause neither its central volume of distribution
or the clearance is significantly affected by body
eight (20). The effect of the regadenoson bolus on
he coronary circulation is due to its concentration
uring the first pass through the heart, which is
redominately independent of the intravascular vol-
me. Insufficient levels of regadenoson are believed
o be present at the second pass because of its short
istribution half-life of 2 min. Thus, the drug
ffect is determined by dilution of the drug bolus as
t mixes with venous blood on its way from the
njection site to the coronary vasculature. The
olume of venous blood diluting regadenoson dur-
ng the short duration of administration as it
eaches the heart for the first time determines the
rug’s effect. This volume is not expected to vary
ignificantly with body weight. Because of ade-
osine’s ultrashort half-life of 10 s (which is too
hort for adequate tracer uptake), it is not suitable
or fixed bolus dosing. Furthermore, a fixed bolus
ose eliminates the need to calculate dose by weight
nd the need for continuous computerized pump
nfusion, which may potentially reduce dosing er-
ors. Subgroup analysis has confirmed fixed bolus
osing of regadenoson was both safe and efficacious
egardless of age, BMI, gender, and DM.
etter tolerance. In addition to its good safety pro-
le and ease of administration, more patients felt
ore comfortable following regadenoson than
denosine administration. This finding was consis-
ent across all subgroups, including females who
verall reported more symptoms than males.
esign features of the ADVANCE MPI trials. The AD-
ANCE MPI trials demonstrated the following
istinctive design features: 1) reflection of real-
orld clinical practice; 2) noninferiority compari-
on; and 3) comparison of agreement rates for
equential imaging.
eal-world clinical practice. The ADVANCE MPI
rials were designed to simulate real-world clinical
ractice by enrolling over 2,000 patients across 109
enters. Selection of protocols and radiotracers was
t the discretion of the investigator and is compa-
able to those used in clinical practices worldwide
21).
oninferiority design. The ADVANCE MPI trials
dhere to the 4 requirements proposed for nonin-
eriority trials: 1) comparison to a reference stan- rard, 2) use of established outcome measurements,
) establishment of a pre-defined margin of inferi-
rity, and 4) avoidance of design features that will
ncrease the risk of falsely concluding noninferiority
9–11,17,18).
We used adenosine, which is an established
harmacologic agent for MPI studies (15,22). For
he second requirement, outcome measurements
imilar to previous adenosine trials were used
13,23). The trials also pre-defined a margin of
nferiority. The combined analysis revealed a differ-
nce of 0% between the 2 agents with a narrow
onfidence interval. Moreover, average agreement
ates were comparable across different measures of
fficacy and pre-defined subpopulations.
Finally, the primary end point comparison was
esigned to reduce the risk of wrongly concluding
oninferiority by ensuring adequate representation
f patients with reversible defects. Because the
tress agent used should not affect results in patients
ithout ischemia, the proportion of patients ran-
omized with initial adenosine studies assessed by
he site investigators as showing no or minimal
eversible defects was limited to 50%, and the
verall agreement rate was defined to give only
ne-third weight to patients in this category.
ariability in SPECT MPI. Another unique feature is
omparison of agreement rates for sequential im-
ges. Knowing the inherent variability of SPECT
maging is critical to determining whether observed
hanges in scan interpretation can be ascribed to
ctual changes due to treatment, changes in the
atient’s condition, or the inherent procedure vari-
bility (14). There are few previous studies evaluat-
ng agreement rates for sequential imaging. These
tudies were single-center, included 20 patients,
sed polar map interpretation, and compared agree-
ent rates using only 1 or 2 readers (24). The
ombined analysis suggests that there is a high
egree of variability in SPECT MPI.
Although regadenoson is comparable to adeno-
ine in determining the extent of reversible defects,
he average agreement rate is approximately 60%.
revious studies (25–28) have reported higher
greement rates. However, the apparent discrep-
ncy may be due to different methodologies used in
he ADVANCE MPI trials and those used in
reviously reported studies.
First, the majority of studies in the literature have
ompared inter-reader interpretation of a single
mage and not 2 sequential images as performed in
he ADVANCE MPI trials (25–28). Agreement
ates for comparison of sequential images may be
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315ower because acquisition of a second image intro-
uces biological changes in the patient’s clinical
ondition and in the medical regimen as well as
echnical variability in acquisition and image pro-
essing of the second image (14,29,30).
Second, previous studies in the literature have
sed sample weighted averages to calculate agree-
ent rates (25–28), which gives the category with
he highest number of patients the greatest contri-
ution to the average. Thus, studies tend to report
igher agreement rates if they enroll more patients
ho have no ischemia. In the ADVANCE MPI
rials, an unweighted average, which gives equal
eight to all categories of ischemia, was used to
alculate agreement rates. This provides a more con-
ervative estimate of agreement and test of inferiority.
Finally, agreement rates in the literature are
sually reported for the overall impression of the
can: normal versus abnormal or normal versus
schemia versus infarct. It is well known from
revious studies on coronary angiography and
PECT that agreement rates are better when cat-
gories are limited (26,31). In the ADVANCE
PI trials, when ischemia categories are collapsed
o presence versus absence of ischemia, agreement
ates increase and approximate published values.
Similar to previous studies, the average agree-
ent rates were highest in the no-to-minimal
schemia size category (80%) and lower (50%)
n the moderate-to-severe ischemia size categories.
hus, readers often agreed upon the presence of
schemia, but they differed with respect to the
xtent of ischemia. The semiquantitative SSS and
DS for adenosine-adenosine comparisons showed
elatively close agreement in the mean difference
nd standard deviations (Fig. 2). Another possible
eason for the variability is that the degree of
harmacological stress produced by the agents dif-
ered between initial and randomized scans. This
ould primarily affect patients with ischemia. The
egree of pharmacological stress would have no
ffect on patients without ischemia. Although the
rotocols were designed to ensure consistent infu-American Heart Association Task tional Union of Phency cannot be controlled. Similar agreement rates,
owever, were noted when collapsing diagnostic
ategories into the presence or absence of ischemia.
tudy limitations. A major limitation of the AD-
ANCE MPI trials is that the trials excluded 2
mportant patient subsets: 1) patients who have
ontraindications to adenosine, and 2) patients who
ad significant symptoms on the initial adenosine
can. Although this does not affect the image com-
arison to adenosine, it underestimates the degree of
ide effects. Additional studies are needed to better
valuate the safety and tolerability of regadenoson in
his subset of patients who may derive greater benefit
rom A2A selectivity. A second limitation of the study
s that there was no formal evaluation of the reduction
f dosing errors and improved lab efficiency associated
ith fixed, bolus dosing. This analysis, however,
ould have been challenging given the double dummy
esign. Finally, it is possible that quantitative analysis
ill decrease variability. Future analysis comparing the
ariability of sequential images using quantitative
ethods is ongoing.
O N C L U S I O N S
egadenoson can be safely administered as a fixed
nit bolus and is as efficacious as adenosine in the
etection of myocardial perfusion reversible defects.
he safety and efficacy of regadenoson have been
emonstrated in all patients regardless of age, gen-
er, BMI, and presence or absence of diabetes.
egadenoson was better tolerated than adenosine
y all patients and subgroups.
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